Palisade Bio Strengthens Phase 2 Case for PALI-2108 with New IBD Data
Event summary
- Palisade Bio presented five posters at ACG 2026, with two winning Presidential Poster Awards
- Phase 1b data showed early clinical activity in UC and fibrostenotic Crohn’s disease
- Microbiome and transcriptomic analyses support targeted delivery and potential precision medicine approach
- Phase 2 studies (ASCENTRA-UC and Crohn’s disease program) are ongoing
The big picture
Palisade Bio’s data reinforces the rationale for its gut-targeted PDE4 inhibitor in IBD, a space dominated by biologics and JAK inhibitors. The microbiome-activated delivery platform could offer a differentiated approach if Phase 2 results hold. Success hinges on demonstrating superior efficacy and tolerability in head-to-head comparisons.
What we're watching
- Clinical Validation
- Whether Phase 2 data will confirm early signals of efficacy in larger, controlled studies
- Precision Medicine
- The pace at which transcriptomic signatures can enable patient stratification
- Competitive Positioning
- How sustained systemic exposure compares to existing PDE4 inhibitors like apremilast
